335P - Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
Saved in:
| Title: | 335P - Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study |
|---|---|
| Authors: | De Laurentiis, M.1 (AUTHOR), Mazza, M.2 (AUTHOR), Mansutti, M.3 (AUTHOR), Masetti, R.4 (AUTHOR), Ballatore, Z.5 (AUTHOR), Torrisi, R.6 (AUTHOR), Michelotti, A.7 (AUTHOR), Zambelli, A.8 (AUTHOR), Ferro, A.9 (AUTHOR), Generali, D.10 (AUTHOR), Vici, P.11 (AUTHOR), Coltelli, L.12 (AUTHOR), Fabi, A.13 (AUTHOR), Marchetti, P.14 (AUTHOR), Ballestrero, A.15 (AUTHOR), Spazzapan, S.16 (AUTHOR), Frassoldati, A.17 (AUTHOR), Sarobba, G.18 (AUTHOR), Grasso, D.19 (AUTHOR), Zamagni, C.20 (AUTHOR) |
| Source: | Annals of Oncology. 2019 Supplement 6, Vol. 30, pv119-v119. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz242.030 |
